PFIZER
Pfizer and Astellas announced the final results of the overall analysis from Phase 3 PROSPER study. The trial enrolled adults with with non-metastatic castration-resistant prostate cancer (nmCRPC). The study evaluated Xtandi plus androgen deprivation therapy (ADT) versus placebo plus ADT.
The risk of death reduced by 27% in Xtandi plus ADT compared to placebo plus ADT. The median OS was 67.0 months compared to 56.3 months in placebo plus ADT arm.
GSK
Belantamab mafodotin
GSK presented the results of DREAMM-2 and DREAMM-6 data in relapsed/refractory multiple myeloma patients.
In DREAMM-2 study, median overall survival was 14.9 months and median duration of response was 11 months.
In DREAMM-6 study, belantamab mafodotin plus bortezomib and dexamethasone resulted in 78% overall response rate.
ROCHE
Alecensa
Roche presented the ALEX study results for patients with ALK-positive non-small cell lung cancer. The trail is intended to confirm the long-term efficacy of Alcensa.
In ALEX study, the overall survival at five years is 62.5 % in Alecensa arm compared to 45.5% in crizotinib arm.
NOVARTIS
Kisqali
Novartis presented the overall survival benefit of its blockbuster product, Kisqali. The company has presented MONALEESA-7 (M7) and MONALEESA-3 (M3) subgroup analysis.
The study confirmed that patients who were administered with Kisqali had extended life compared to normal endocrine therapy. The reduction in death was ~47% and 37% in M7 and M3 studies respectively.
Comments